Hims & Hers Shares Edge Higher Ahead of Key FDA Advisory Meeting
Hims & Hers Health Inc. traded slightly higher in pre-market action, keeping near $31.54 after attention around a Leerink Partners note that outlined how a July regulatory review could enable the telehealth company to enter peptide compounding. The company is being valued largely on regulatory optionality ahead of a July 23-24 Pharmacy Compounding …